NorthWest Biotherapeutics Inc (NWBO)

[10baggerz]

Great post/question. As usual I'm sure it's multifactorial. Just off the top of my head:Time-elapsed since start of trials, company finanances preventing pre-approval PR blitzes, quality and connections of investor relations, lack of perception that dendritic cells are cutting edge technologies, lack of respect of a company trading on the OTC, LP's lack of social skills and social media presence, the fact that management are all introverted lawyers not salespeople, the fact that they chose one of the rarest cancers to do a PIII trial and have not initiated any trials since so the public interest is exponentially less in GBM alone, etc.